

of life outcomes of a randomised, open-label, phase 3 trial. *Lancet Haematol.* 2020;7(12):e874-e883. doi: 10.1016/S2352-3026(20)30356-2.

84. Hulin C, Offner F, Moreau P, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. *Haematologica.* 2021;106(8):2257-2260. doi: 10.3324/haematol.2020.261842.

85. Mohyuddin GR, Mian H. Daratumumab in newly diagnosed MM – incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. *Nat Rev Clin Oncol.* 2022;19(1):3-4. doi: 10.1038/s41571-021-00581-2.

86. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. *N Engl J Med.* 2019;380:2104-2115.

87. Jain A, Ramasamy K. Evolving Role of Daratumumab: From Backbencher to Frontline Agent. *Clin Lymphoma Myeloma Leuk.* 2020;20(9):572-587. doi:10.1016/j.clml.2020.03.010.

88. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6.

89. Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. *Leukemia.* 2022;36(4):1066-1077. doi: 10.1038/s41375-021-01488-8.

90. Faith D, Rifkin R, Costello C, Hájek R. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. *Annals of hematology.* 2021;100(9):2325-2337.

91. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood.* 2020;136(8):936-945. doi: 10.1182/blood.2020005288.

92. Voorhees PM, Rodriguez C, Reeves B, et al. Daratumumab plus RVD for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. *Blood Adv.* 2021;5(4):1092-1096. doi:10.1182/bloodadvances.2020003642.

93. Nooka AK, Kaufman JL, Rodriguez C, et al. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. *Blood Cancer J.* 2022;12(4):63. doi: 10.1038/s41408-022-00653-1.

94. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. *Br J Haematol.* 2019;185(3):492-502. doi: 10.1111/bjh.15806.

95. Yimer H, Melear J, Faber E, et al. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. *Leuk Lymphoma.* 2022;1-10. doi: 10.1080/10428194.2022.2076847.

96. Landgren O, Hultcrantz M, Diamond B, et al. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. *JAMA Oncol.* 2021;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611.

97. Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. *J Clin Oncol.* 2021 Dec 13;JCO2101935. doi: 10.1200/JCO.21.01935.

98. NCCN Guidelines Version 4.2022, Multiple Myeloma, https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed 1.22.2022.

99. Giri S, Grimshaw A, Bal S. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-

risk Cytogenetic Factors: A Systematic Review and Meta-analysis. *JAMA Oncol.* 2020;6(11):1759-1765. doi: 10.1001/jamaoncol.2020.4338.

100. Weisel K, Spencer A, Lentzsch S, et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. *J Hematol Oncol.* 2020;13(1):115-120. doi: 10.1186/s13045-020-00948-5.

101. Jakubowiak AJ, Kumar S, Medhekar R, et al. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. *Oncologist.* 2022 Apr 24;oyac067. doi: 10.1093/oncolo/oyac067.

102. Kaufman JL, Dimopoulos MA, White D, et al. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. *Blood Cancer J.* 2020 Nov 3;10(11):111. doi: 10.1038/s41408-020-00375-2.

103. Wang Y, Li Y, Chai Y. Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis. *J Int Med Res.* 2021;49(8):3000605211038135. doi: 10.1177/03000605211038135.

104. Landgren O, Weisel K, Rosinol L, et al. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. *Br J Haematol.* 2022 May 24. doi: 10.1111/bjh.18233.

105. Rene CG, Achiam MP, Salomo M, et al. Extramedullary relapse in a patient with multiple myeloma: a rare cause of gastrointestinal perforation and massive bleeding. *BMJ Case Rep.* 2021;14(11):e243663. doi:10.1136/bcr-2021-243663.

106. Uslu A, Seval GC, Merter M. Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review. *Clin Lymphoma Myeloma Leuk.* 2021;21(3):e267-e271. doi: 10.1016/j.clml.2020.11.017.

107. Mohamed M, Alhillan A, Gupta V, Nahum K, et al. Relapsing Cutaneous Multiple Myeloma Responding to Immunotherapy: A Rare Case Report. *J Med Cases.* 2019;10(10):305-308. doi: 10.14740/jmc3382.

108. Gozzetti A, Cerase A, Bocchia M. Daratumumab efficacy in extramedullary orbital myeloma. *Clin Case Rep.* 2020;8(12):3652-3653. doi: 10.1002/ccr3.3458.

109. Moreno DF, Clapés V, Soler JA, et al. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. *Clin Lymphoma Myeloma Leuk.* 2022 Apr 17: S2152-2650(22)00126-4. doi: 10.1016/j.clml.2022.04.014.

110. Jelinek T, Ševčíková T, Žihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. *Leukemia.* 2022;36(1):288-291.

111. Jelinek T, Maisnar V, Pour L, et al. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. *Current medical research and opinion.* 2018;34(5):775-783.

112. Harvanová L, Štulajterová V, Guman T, et al. A Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia. *Neoplasma.* 2021;68(3):626-630. doi: 10.4149/neo_2021_201113N1223.

113. Vela-Ojeda J, Gómez-Almaguer D, Espinoza-Zamora R, et al. Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico. *Arch Med Res.* 2021;52(6):627-634. doi: 10.1016/j.arcmed.2021.02.008.

114. Pick M, Vainstein V, Goldschmidt N, et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. *Eur J Haematol.* 2018;100(5):494-501. doi: 10.1111/ejh.13046.

115. Zajec M, Frerichs KA, van Duijn MM, et al. Cerebrospinal Fluid Penetration of Daratumumab in Leptomeningeal Multiple Myeloma. *Hemasphere.* 2020;4(4):e413. doi: 10.1097/

HS9.0000000000000413.

116. Elhassadi E, Murphy M, Hacking D, et al. Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. *Clin Case Rep.* 2018;6(4):723-728. doi: 10.1002/ccr3.1451.

117. Dispenzieri A. Monoclonal gammopathies of clinical significance. *Hematology Am Soc Hematol Educ Program.* 2020;1(1):380-388. doi: 10.1182/hematology.2020000122.

118. Lecumberri R, Krsnik I, Askari E, et al. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: A multicentric retrospective study and review of the literature. *Amyloid.* 2020;27(3):163-167.

119. Roussel M, Merlini G, Chevret S, et al. A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients. *Blood.* 2020;135:1531.

120. Sanchurawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. *Blood.* 2020;135(18):1541-1547. doi: 10.1182/blood.2019004436.

121. Palladini G, Kastiris E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. *Blood.* 2020;136(1):71-80. doi:10.1182/blood.2019004460.

122. Kastiris E, Palladini G, Minnema MC, et al. ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. *N Engl J Med.* 2021;385(1):46-58. doi: 10.1056/NEJMoa2028631.

123. Sanchurawala V, Palladini G, Minnema MC, et al. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. *Am J Hematol.* 2022;97(6):719-730. doi: 10.1002/ajh.26536.

124. Kaufman GP, Cerchione C. Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. *Front Oncol.* 2021;10:624573. doi: 10.3389/fonc.2020.624573.

125. Theodorakakou F, Dimopoulos MA, Kastiris E. Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. *Ther Adv Hematol.* 2021;12:20406207211058334. doi: 10.1177/20406207211058334.

126. Janssen Biotech Darzalex+ Faspro (daratumumab and hyaluronidase-fihj) [package insert]. U.S. food and drug administration. Accessed from: <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+ Faspro-pi.pdf>. 2022; 20 January.

127. Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. *Blood.* 2020;135(18):1517-1530. doi: 10.1182/blood.2019003633.

128. Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. *Am J Hematol.* 2020;95(8):900-905. doi: 10.1002/ajh.25828.

129. Sammartano V, Antonoli E, Buda G, et al. Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscany Myeloma Network). *J Pers Med.* 2022 Mar 17;12(3):484. doi: 10.3390/jpm12030484. PMID: 35330483; PMCID: PMC8952680.

130. Mar E, Taylor K, Mollee P. Response of factor X deficiency to daratumumab in the treatment of AL amyloidosis: a novel finding. *BMJ Case Rep.* 2021;14(4):e240631.

131. Chaulagain CP, Herlitz LC, Fu J, et al. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AL Amyloidosis). *Clin Lymphoma Myeloma Leuk.* 2020;20(11):e826-e831. doi: 10.1016/j.clml.2020.06.017.

132. Shimamura Y, Ogawa Y, Takizawa H, et al. Light Chain Deposition Disease Diagnosed Using Computed Tomography-Guided Kidney Biopsy. *Cureus.* 2021;13(5):e15102. doi: 10.7759/cureus.15102.

133. Kastiris E, Rousakis P, Kostopoulos IV, et al. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. *Amyloid.*